| Biomarker ID | 1673 |
| PMID | 25847734 |
| Year | 2015 |
| Biomarker | fPSA + p2PSA |
| Biomarker Basis | Concentration Based (pg/mL) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in PCa (PCa: 48.62; No PCa: 33.35) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | PCa Vs No PCa |
| Type of Biomarker | Diagnostic |
| Cohort | 250 patients, 112 with Prostate cancer and 138 with No prostate cancer were selected for analysis |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.678 (95% CI: 0.610-0.745) |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | Immunoassays |
| Clinical | No |
| Remarks | 10 fold cross validation was performed |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |